# US 2021/0275668 A1 · Combination of factor vii and an anti-factor ix/x bispecific antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275668 A1
- Document ID: US20210275668A1
- Status: Published application
- Kind: A1
- Application number: 17/251,695
- Filed: 2019-06-14
- Published: 2021-09-09
- Earliest claimed: 2018-06-14
- Assignees: Laboratoire Français du Fractionnnement et des Biotechnologies
- Applicants: Laboratoire Français du Fractionnnement et des Biotechnologies
- Inventors: Jean-Luc Plantier
- Web page: https://patentgrep.com/patent/US20210275668A1

## CPC

- A61K 38/46: Hydrolases (3)
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C07K 16/36: against blood coagulation factors
- C12Y 304/21021: Coagulation factor VIIa (3.4.21.21)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/75: Agonist effect on antigen
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The invention concerns a combination comprising transgenic factor VII and a multispecific antibody directed against factor IX and X, for simultaneous or separate administration.

## Claims

### Claim 1

Pharmaceutical composition comprising:
a. transgenic factor VII, and
b. a multispecific antibody directed against factor IX and factor X,

### Claim 2 (depends on 1)

Pharmaceutical composition according to claim 1, wherein said transgenic factor VII is a human factor VII derived from production by epithelial cells of the mammary glands of a transgenic non-human mammal.

### Claim 3 (depends on 2)

Pharmaceutical composition according to claim 2, wherein said transgenic mammal is a rabbit.

### Claim 4 (depends on 1, 2, 3)

Pharmaceutical composition according to any one of claims 1 to 3, wherein the antibody is emicizumab.

### Claim 5

Combination product comprising:
a. transgenic factor VII, and
b. a multispecific antibody directed against factor IX and factor X,
for its use in preventing or treating a coagulation disorder in a patient.

### Claim 6 (depends on 5)

Combination product according to claim 5, in the treatment of hemophilia A.

### Claim 7 (depends on 5, 6)

Combination product according to one of claim 5 or 6 in the treatment of hemophilia A with factor VIII inhibitors.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

Combination product for its use according to claims 5 to 7, said combination product being in the form of a pharmaceutical composition such as defined in any one of claims 1 to 4.

### Claim 9 (depends on 5, 6, 7, 8)

Combination product for its use according to claims 5 to 8, said factor Vila and said antibody being in a form suited to simultaneous administration to the patient.

### Claim 10 (depends on 5, 6, 7, 8)

Combination product for its use according to claims 5 to 8, said factor Vila and said antibody being in forms suited to separate administration to the patient.

### Claim 11

Kit comprising
A container containing transgenic factor FVII; and
Another container containing an antibody directed against factor IX and factor X.

### Claim 12

Method to treat a coagulation disorder in a patient, which method comprises the simultaneous or sequential administration to said patient of transgenic factor VII and a multispecific antibody directed against factor IX and factor X.

### Claim 13

Use of a combination of transgenic factor VII and a multispecific antibody directed against factor IX and factor X for the treatment of a coagulation disorder in a patient, preferably hemophilia A, with factor VIII inhibitors.
